Bromocriptine treatment of digitalis-induced ventricular tachyarrhythmias: studies in a canine model.

Bromocriptine treatment of digitalis-induced ventricular tachyarrhythmias: studies in a canine model.
复制标题

溴隐亭治疗洋地黄引起的室性快速心律失常:犬模型研究。

DOI:
10.1016/s0735-1097(84)80137-0
复制
发表时间:
1984
影响因子:
24
通讯作者:
D. Benditt
D. Benditt
中科院分区:
医学1区
文献类型:
--
作者:
A. Kao;J. Kriett;H. Tobler;B. L. Detloff;M. Pritzker;D. Benson;D. Benditt

文献摘要

被引文献

相似文献

Ventricular tachyarrhythmias associated with digitalis toxicity are believed to be due, in part, to cardiac glycoside-mediated increased central sympathetic neural activity. Because dopaminergic receptor agonists reduce sympathetic outflow, this study assessed effectiveness of the available dopaminergic agonist, bromocriptine, in slowing or terminating ouabain-induced ventricular tachycardia in anesthetized dogs. In all experiments, ouabain was administered intravenously (20μg/kg body weight bolus injection, followed by 2.5μg/kg per min infusion) until the onset of stable ventricular tachycardia.Of seven untreated dogs (Group 1), ouabain-induced ventricular tachyarrhythmias resulted in ventricular fibrillation in three, while in four dogs tachycardia persisted without significant change in rate until the study was terminated. Fourteen dogs (Group 2) received bromocriptine, either 30μg/kg (Group 2A) or 50μg/kg (Group 2B), after the onset of ventricular tachycardia. Tachycardia slowed in all 14 dogs and terminated with resumption of sinus rhythm in 8 of the 14. In all six dogs pretreated with the peripheral dopaminergic antagonist domperidone (Group 3), bromocriptine, 50μg/kg, slowed ventricular tachycardia and in three of the six, tachycardia terminated. In contrast, of five dogs pretreated with haloperidol, a central and peripheral dopaminergic receptor antagonist (Group 4), bromocriptine, 50μg/kg, failed to slow ventricular tachycardia in three, and two of the three developed ventricular fibrillation.In summary, the dopaminergic receptor agonist, bromocriptine, presumably acting at central dopaminergic receptor sites, consistently slowed and in most cases reversed ouabain-induced ventricular tachycardia in a canine model.